KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Gross Margin (2016 - 2025)

Historic Gross Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 71.89%.

  • Bristol Myers Squibb's Gross Margin fell 32400.0% to 71.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 69.5%, marking a year-over-year decrease of 54100.0%. This contributed to the annual value of 71.08% for FY2024, which is 51600.0% down from last year.
  • Bristol Myers Squibb's Gross Margin amounted to 71.89% in Q3 2025, which was down 32400.0% from 72.52% recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Gross Margin peaked at 80.34% during Q4 2021, and registered a low of 61.01% during Q4 2024.
  • For the 5-year period, Bristol Myers Squibb's Gross Margin averaged around 75.43%, with its median value being 76.08% (2023).
  • As far as peak fluctuations go, Bristol Myers Squibb's Gross Margin soared by 83100bps in 2021, and later plummeted by -150700bps in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Gross Margin stood at 80.34% in 2021, then dropped by -4bps to 77.27% in 2022, then dropped by -2bps to 76.08% in 2023, then dropped by -20bps to 61.01% in 2024, then increased by 18bps to 71.89% in 2025.
  • Its last three reported values are 71.89% in Q3 2025, 72.52% for Q2 2025, and 72.92% during Q1 2025.